“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being ...

When it comes to bladder cancer, it’s important to note the differences between muscle-invasive and non-muscle-invasive bladder cancer, as it can affect the staging of the cancer. The “stage” (spread) ...

Merck’s Keytruda is riding a winning streak in bladder cancer. Following FDA approvals in the metastatic and non-muscle invasive settings, the anti-PD-1 therapy has delivered a positive readout in ...

ImmunityBio says Anktiva plus BCG showed durable survival and bladder preservation at 36 months in BCG-unresponsive bladder cancer patients.

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its ...

Kolschowsky Research and Education Institute at Sarasota Memorial Hospital is seeking candidates diagnosed with ...

Emerging solutions are bringing us closer than ever to tackling these unmet medical needs, enhancing patient outcomes and improving overall quality of life for those with NMIBC. Cretostimogene ...